Increased our 2025 full-year revenue guidance to be in the range of $63.0 billion to $63.5 billion; reported EPS guidance raised to be in the range of $21.80 to $22.50 and non-GAAP EPS guidance raised ...

Pfizer filed a second lawsuit on Monday accusing Danish drugmaker Novo Nordisk of structuring its $9 billion bid for Metsera to stall the entry of the biotech firm's treatments into the obesity drug ...

Pfizer has filed a second lawsuit against Danish pharmaceutical giant Novo Nordisk, accusing the company of deliberately stalling its $9 billion bid for biotech firm Metsera to hinder competition in ...

Such conversations are becoming increasingly common as demand for weight-loss drugs explodes in urban India - a country with ...

Metsera's shareholders are scheduled to meet on November 13 to decide on Novo Nordisk's offer of around $8.5 billion, while ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

A rendering of Eli Lilly's planned plant expansion in Pleasant Prairie. The company is preparing for a next phase on a site ...

Determining the type of diabetes a patient has at diagnosis can be challenging, and health care professionals should focus on each patient’s clinical condition when determining initial treatment, ...

The healthcare industry has proven to be a resilient place for investors to put cash to work over the years. If you are ...

Tirzepatide, a medication sold under the names Mounjaro for diabetes and Zepbound for weight loss, has shown impressive results in helping people avoid developing diabetes. A new study found that it ...

Biotech Viking Therapeutics has gained prominence over the past two years, but it could have plenty of upside left.

Novo Nordisk made a surprise bid for Metsera to boost its weight-loss market lead, trading at just 12x 2026 EPS. Read why NVO ...